Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia

Leukemia volume 29, pages 2107–2110 (2015)Cite this article

Subjects

Philadelphia-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) identifies an unfavorable subgroup of pediatric ALL characterized by the presence of the BCR-ABL1 chimeric protein. However, clinically Ph+ BCP-ALL remains a heterogeneous disease with an unfavorable response to therapy in a critical percentage of patients. Even though introduction of tyrosine kinase inhibitors (TKIs) has improved outcome in pediatric Ph− BCP-ALL patients, 30% still relapse or die.1

Recurrent genomic deletions within the IKAROS (IKZF1) gene locus have been identified in Ph+ BCP-ALL2 and BCP-ALL in general, and recent the work of van der Veer et al.3 has shown that clinical heterogeneity in response to therapy at least in part may be attributed to the mutation status of IKZF1 in Ph+ BCP-ALL patients.4, 5

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936–945.

    Article  CAS  Google Scholar 

  2. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110–114.

    Article  CAS  Google Scholar 

  3. Van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014; 123: 1691–1698.

    Article  CAS  Google Scholar 

  4. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470–480.

    Article  CAS  Google Scholar 

  5. Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica 2013; 98: 1226–1231.

    Article  CAS  Google Scholar 

  6. Sun L, Liu A, Georgopoulos K . Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. EMBO J 1996; 15: 5358–5369.

    Article  CAS  Google Scholar 

  7. Schjerven H, McLaughlin J, Arenzana TL, Frietze S, Cheng D, Wadsworth SE et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat Immunol 2013; 14: 1073–1083.

    Article  CAS  Google Scholar 

  8. Cobb BS, Morales-Alcelay S, Kleiger G, Brown KE, Fisher AG, Smale ST . Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. Genes Dev 2000; 14: 2146–2160.

    Article  CAS  Google Scholar 

  9. Kastner P, Dupuis A, Gaub M-P, Herbrecht R, Lutz P, Chan S . Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res 2013; 3: 1–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153–166.

    Article  CAS  Google Scholar 

  11. Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010; 28: 4755–4761.

    Article  Google Scholar 

  12. Kohlmann A, Klein H-U, Weissmann S, Bresolin S, Chaplin T, Cuppens H et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011; 25: 1840–1848.

    Article  CAS  Google Scholar 

  13. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248–249.

    Article  CAS  Google Scholar 

  14. Ng PC, Henikoff S . Predicting deleterious amino acid substitutions. Genome Res 2001; 11: 863–874.

    Article  CAS  Google Scholar 

  15. Raetz EA, Carroll WL . Refining prognosis in BCR-ABL1-positive ALL. Blood 2014; 123: 1626–1627.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr Aurélie Caye and all the pediatricians from the Société Française des Cancer de l’Enfant (SFCE). This work was supported by Czech Ministry of Health NT 13170-4 (to MZ), Czech Science Foundation GACR (grant P304/12/2214 to EF), the Italian Associations for Cancer Research (AIRC, to CG), the Italian Ministry of University and Research (MIUR, to AB) and the Fondazione Cariplo (to CG and GtK). The research leading to these results has received funding from the European Union’s Seventh Framework Program (PF7/2007-2013) under the project ENCCA, grant agreement HEALTH-F2-2011-261474 (MGV, GtK, MS, GC, AB and MLdB) and ERA-net TRANSCAN project TRANSCALL (GB, MS, GC and GtK).

Disclaimer

These funding sources had no role in the collection, analysis or interpretation of the results, or in writing the manuscript and the decision for submission of this work.

Author information

Authors and Affiliations

  1. Department of Women’s and Children’s Health, University of Padova, Padova, Italy

    T Lana, S Bresolin, I Bronzini, G Basso & G te Kronnie

  2. Clinica Pediatrica, Centro Ricerca Tettamanti, University of Milano-Bicocca, Monza, Italy

    P de Lorenzo, A Biondi & G Cazzaniga

  3. Department of Health Sciences, European Study for Philadelphia–Acute Lymphoblastic Leukemia Trial Data Center, University of Milano-Bicocca, Monza, Italy

    P de Lorenzo & M G Valsecchi

  4. Department of Pediatric Oncology, Erasmus University Medical Center-Sophia Children’s Hospital, Rotterdam, The Netherlands

    M L den Boer

  5. Dutch Childhood Oncology Group, The Hague, The Netherlands

    M L den Boer & H de Groot

  6. Department of Genetics, Assistance Publique Hôpitaux de Paris, Hôspital Robert Debré, University Paris Diderot, Paris, France

    H Cavé

  7. Childhood Leukemia Investigation Prague, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic

    E Froňková & M Zaliova

  8. Department of Pediatric Hematology and Oncology, Hannover Medical School, Germany

    M Stanulla & M Zaliova

  9. Department of General Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany,

    M Stanulla & M Zaliova

  10. Leukemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK,

    C J Harrison

Authors
  1. T Lana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P de Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Bresolin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Bronzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M L den Boer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Cavé
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Froňková
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Stanulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Zaliova
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C J Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H de Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M G Valsecchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Biondi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. G Basso
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G Cazzaniga
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. G te Kronnie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G te Kronnie.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lana, T., de Lorenzo, P., Bresolin, S. et al. Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. Leukemia 29, 2107–2110 (2015). https://doi.org/10.1038/leu.2015.78

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.78

This article is cited by

Search

Advanced search

Quick links